HRP20100629T1 - Kristalni oblik spoja kinolinon-karboksamida - Google Patents

Kristalni oblik spoja kinolinon-karboksamida Download PDF

Info

Publication number
HRP20100629T1
HRP20100629T1 HR20100629T HRP20100629T HRP20100629T1 HR P20100629 T1 HRP20100629 T1 HR P20100629T1 HR 20100629 T HR20100629 T HR 20100629T HR P20100629 T HRP20100629 T HR P20100629T HR P20100629 T1 HRP20100629 T1 HR P20100629T1
Authority
HR
Croatia
Prior art keywords
compound
crystalline salt
crystalline
salt
peak values
Prior art date
Application number
HR20100629T
Other languages
English (en)
Croatian (hr)
Inventor
R. Fatheree Paul
Derek Turner S.
Goldblum Adam
Chao Robert
Genov Daniel
Original Assignee
Theravance
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance filed Critical Theravance
Publication of HRP20100629T1 publication Critical patent/HRP20100629T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20100629T 2005-04-06 2006-04-05 Kristalni oblik spoja kinolinon-karboksamida HRP20100629T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06
PCT/US2006/012978 WO2006108127A2 (en) 2005-04-06 2006-04-05 Crystalline form of a quinolinone-carboxamide compound

Publications (1)

Publication Number Publication Date
HRP20100629T1 true HRP20100629T1 (hr) 2010-12-31

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100629T HRP20100629T1 (hr) 2005-04-06 2006-04-05 Kristalni oblik spoja kinolinon-karboksamida

Country Status (29)

Country Link
US (4) US7728004B2 (https=)
EP (1) EP1874766B1 (https=)
JP (2) JP5230407B2 (https=)
KR (1) KR101322873B1 (https=)
CN (1) CN101151264B (https=)
AR (2) AR053208A1 (https=)
AT (1) ATE479682T1 (https=)
AU (1) AU2006232129B2 (https=)
BR (1) BRPI0610657A2 (https=)
CA (1) CA2603654C (https=)
CY (1) CY1111275T1 (https=)
DE (1) DE602006016586D1 (https=)
DK (1) DK1874766T3 (https=)
EA (1) EA012115B1 (https=)
ES (1) ES2350495T3 (https=)
HR (1) HRP20100629T1 (https=)
IL (1) IL186023A (https=)
MA (1) MA29403B1 (https=)
MX (1) MX2007012438A (https=)
MY (1) MY151075A (https=)
NO (1) NO339699B1 (https=)
NZ (1) NZ561900A (https=)
PE (1) PE20061310A1 (https=)
PL (1) PL1874766T3 (https=)
PT (1) PT1874766E (https=)
SI (1) SI1874766T1 (https=)
TW (1) TWI377206B (https=)
WO (1) WO2006108127A2 (https=)
ZA (1) ZA200708071B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7399862B2 (en) * 2004-11-05 2008-07-15 Theravance, Inc. 5-HT4 receptor agonist compounds
WO2006052889A2 (en) 2004-11-05 2006-05-18 Theravance, Inc. Quinolinone-carboxamide compounds
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
EP2160188A2 (en) * 2007-05-17 2010-03-10 Theravance, Inc. Prokinetic agent for bowel preparation
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
SMT201800036T1 (it) * 2009-04-13 2018-03-08 Theravance Biopharma R&D Ip Llc Combinazioni di agonisti di recettore 5-ht4 e inibitori di acetilcolinesterasi per il trattamento di disturbi cognitivi
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
KR102692887B1 (ko) * 2017-07-31 2024-08-08 알파시그마 에스.피.에이. 벨루세트라그를 사용하여 위마비 증상을 치료하는 방법
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
CA3263063A1 (en) 2022-09-20 2024-03-28 Alfasigma S.P.A. VELUSETRAG INTENDED FOR USE IN THE TREATMENT OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION (CIPO)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
CA2097815C (en) * 1990-12-28 2001-04-17 Fumio Suzuki Quinoline derivative
WO1994012497A1 (fr) 1992-11-20 1994-06-09 Taisho Pharmaceutical Co., Ltd. Compose heterocyclique
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW548103B (en) * 1997-07-11 2003-08-21 Janssen Pharmaceutica Nv Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
BRPI0416813A (pt) 2003-11-24 2007-03-06 Pfizer compostos de ácido quinolonacarboxìlico com atividade agonista do receptor 5-ht4
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
WO2006052889A2 (en) 2004-11-05 2006-05-18 Theravance, Inc. Quinolinone-carboxamide compounds
US7399862B2 (en) 2004-11-05 2008-07-15 Theravance, Inc. 5-HT4 receptor agonist compounds
WO2006088988A1 (en) 2005-02-17 2006-08-24 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
CN101163701A (zh) 2005-03-02 2008-04-16 施万制药 作为5-ht4受体激动剂的喹啉酮化合物
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
PL1874766T3 (pl) 2011-02-28
CN101151264B (zh) 2011-07-06
AU2006232129A1 (en) 2006-10-12
MA29403B1 (fr) 2008-04-01
JP5230407B2 (ja) 2013-07-10
CN101151264A (zh) 2008-03-26
WO2006108127A3 (en) 2007-01-04
EA012115B1 (ru) 2009-08-28
IL186023A0 (en) 2008-01-20
EA200702161A1 (ru) 2008-04-28
US20060229332A1 (en) 2006-10-12
WO2006108127A2 (en) 2006-10-12
NO20075574L (no) 2007-11-02
JP2008535848A (ja) 2008-09-04
ZA200708071B (en) 2008-10-29
CA2603654C (en) 2014-05-27
SI1874766T1 (sl) 2010-12-31
AU2006232129B2 (en) 2012-07-12
CA2603654A1 (en) 2006-10-12
MX2007012438A (es) 2007-12-05
AR110019A2 (es) 2019-02-13
CY1111275T1 (el) 2015-08-05
NO339699B1 (no) 2017-01-23
US7728004B2 (en) 2010-06-01
US20160095849A1 (en) 2016-04-07
PE20061310A1 (es) 2007-01-23
IL186023A (en) 2011-09-27
TW200643020A (en) 2006-12-16
ATE479682T1 (de) 2010-09-15
DE602006016586D1 (de) 2010-10-14
NZ561900A (en) 2010-12-24
ES2350495T3 (es) 2011-01-24
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
US20140256769A1 (en) 2014-09-11
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
PT1874766E (pt) 2010-11-30
MY151075A (en) 2014-03-31
KR20070116988A (ko) 2007-12-11
JP2012153725A (ja) 2012-08-16
US20100197728A1 (en) 2010-08-05
US9126994B2 (en) 2015-09-08
EP1874766A2 (en) 2008-01-09
KR101322873B1 (ko) 2013-10-30
TWI377206B (en) 2012-11-21
AR053208A1 (es) 2007-04-25
BRPI0610657A2 (pt) 2010-07-13
HK1110866A1 (en) 2008-07-25

Similar Documents

Publication Publication Date Title
HRP20100629T1 (hr) Kristalni oblik spoja kinolinon-karboksamida
TWI429435B (zh) （２ｓ，３ｒ）－ｎ－（２－（（３－吡啶基）甲基）－１－氮雜雙環〔２．２．２〕辛－３－基）苯并呋喃－２－甲醯胺，其新穎鹽形式及使用方法
JP7095106B2 (ja) オキサジアゾール一過性受容器電位チャネル阻害剤
CA2428039C (en) Serotonergic agents
AU2018379992B2 (en) Nonracemic mixtures and uses thereof
WO2022014680A1 (ja) 置換ピペリジン化合物及びその用途
JP2008535848A5 (https=)
AU2002237654A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
PL211082B1 (pl) Pochodne piperydyny, ich zastosowanie, zawierająca je kompozycja i sposób ich wytwarzania
TW202506104A (zh) 氘化有機化合物及其用途（一）
KR20240132476A (ko) 중수소화 유기 화합물 및 이의 용도
KR20240132477A (ko) 중수소화 유기 화합물 및 이의 용도
WO2008080290A1 (en) Selective m4 receptor antagonist and its medical use
JP6936257B2 (ja) Ｅａａｔ３阻害剤としてのピラゾール化合物
TW202024035A (zh) 用於製備(-)-琥珀酸西苯唑啉的新穎方法
CN113784755B (zh) 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
CN101597260A (zh) 新的毒蕈碱受体拮抗剂及其用途
US20100069389A1 (en) Novel forms of reboxetine
JP2004526753A (ja) ［１，４］−ジアゼパン−１−カルボン酸誘導体、それらの製造方法およびタキキニンアンタゴニストとしてのそれらの使用
JP2004501060A (ja) オピオイド受容体に対する親和性を有する３級アミノ化合物
IL266624B2 (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
JP5546684B2 (ja) アミド−トロパン誘導体
WO2003078441A1 (en) Aminomethyl-substituted thiazolobenzimidazole derivative
HK1057864B (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders